Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge (Q37777021)

23 August 2017

1 reference

title

Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge (English)

1 reference

23 August 2017

0 references

1 reference

2

D. A. Cameron

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20676126

14 June 2024

author name string

A. F. Munro

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20676126

14 June 2024

J. M S. Bartlett

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20676126

14 June 2024

language of work or name

English

0 references

publication date

2 August 2010

1 reference

full work available at URL

23 August 2017

https://www.nature.com/articles/onc2010286.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/ONC.2010.286

https://www.nature.com/articles/onc2010286

14 June 2024

1 reference

https://api.crossref.org/works/10.1038/ONC.2010.286

14 June 2024

1 reference

23 August 2017

volume

29

1 reference

23 August 2017

issue

38

1 reference

23 August 2017

page(s)

5231-5240

1 reference

High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

DNA topoisomerase II, genotoxicity, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Metastatic breast cancer survival according to HER2 and Topo2a gene status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Evaluating HER2 amplification and overexpression in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Role of anthracyclines in the era of targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Depression of MAD2 inhibits apoptosis of gastric cancer cells by upregulating Bcl-2 and interfering mitochondrion pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Stromal gene expression predicts clinical outcome in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

A role for BRCA1 in sporadic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol I

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Complex roles of tissue inhibitors of metalloproteinases in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Growth factors. Clinical implications in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

BRCA gene structure and function in tumor suppression: a repair-centric perspective.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

The Rb/E2F pathway and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Recent advances in p53 research: an interdisciplinary perspective.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

HER-2 and topoisomerase II as predictors of response to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Connexin26 expression is associated with lymphatic vessel invasion and poor prognosis in human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Coordinates in the universe of node-negative breast cancer revisited.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Detection of labile anthracycline-DNA adducts by real-time PCR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Evaluation of biological pathways involved in chemotherapy response in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

TIMP-1 as a tumor marker in breast cancer--an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.286

Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis

31 March 2020

series ordinal

4

1 reference

https://api.crossref.org/works/10.1038/ONC.2010.286

Journal of Clinical Oncology

14 June 2024

7

26

1

JMS Bartlett

2008

1 reference

https://api.crossref.org/works/10.1038/ONC.2010.286

14 June 2024

Identifiers

DOI

10.1038/ONC.2010.286

1 reference

23 August 2017

1 reference